# Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

> **NCT07732413** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Lumos Pharma** · enrollment: 30 (estimated)

## Conditions studied

- Progressive Pediatric Brain Cancer

## Interventions

- **DRUG:** NLG802 (indoximod Prodrug)
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07732413
- **Lead sponsor:** Lumos Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-08
- **Primary completion:** 2030-10-08
- **Final completion:** 2030-10-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732413, "Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*